SeaStar Medical, Inc.


SeaStar Medical is a medical technology company focused on redefining extracorporeal therapies to mitigate the effects of excessive inflammation on vital organs. Their innovative solutions, particularly the Selective Cytopheretic Device (SCD), aim to improve outcomes for critically ill patients by addressing dysregulated immune responses that can lead to severe complications such as acute kidney injury and multi-organ failure.

Industries

health-care
manufacturing
medical
medical-device

Nr. of Employees

small (1-50)

SeaStar Medical, Inc.

Denver, Colorado, United States, North America


Products

Selective cytopheretic device for pediatric AKI (humanitarian device)

An inline extracorporeal cartridge intended to treat pediatric patients (weight ≥ 10 kg and age ≤ 22 years) with acute kidney injury due to sepsis when used within a CKRT circuit; approved under a Humanitarian Device Exemption for this indication.

Selective cytopheretic device for adult AKI and other indications (investigational)

An extracorporeal immunomodulation cartridge under clinical investigation for adult acute kidney injury requiring CRRT and other indications (e.g., cardiorenal syndrome, hepatorenal syndrome, chronic systemic inflammation in ESRD).


Services

Clinical trial sponsorship and execution

Design and conduct of adult and pediatric clinical studies evaluating device safety and efficacy, including endpoint selection, patient follow-up, and publication of results.

Device implementation and hospital onboarding support

Assessment of clinical infrastructure compatibility, guidance for integrating the extracorporeal cartridge into existing CKRT workflows, and support for institution enrollment in surveillance registries.

Registry-based post-market surveillance (SAVE Surveillance Registry)

Collection and analysis of real-world clinical outcomes from sites using the therapy to monitor safety and effectiveness over time.

Regulatory and evidence support for device adoption

Support for regulatory pathways including Humanitarian Device Exemption submissions and engagement around Breakthrough Device Designation programs; generation of clinical evidence to support regulatory filings.

Expertise Areas

  • Cell-directed extracorporeal therapy
  • Critical care clinical trial management
  • Acute kidney injury (AKI) therapeutics
  • Device-based immunomodulation targeting neutrophils and monocytes
  • Show More (2)

Key Technologies

  • Extracorporeal cartridge-based immunomodulation
  • Continuous kidney replacement therapy (CKRT) integration
  • Regional citrate anticoagulation (RCA) compatibility
  • Targeted modulation of neutrophils and monocytes
  • Show More (3)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.